Pathogenic Flaviviruses: Molecular Mechanisms Of Disease, Host Response And Vaccines
Funder
National Health and Medical Research Council
Funding Amount
$697,209.00
Summary
The application is aimed at advancing our understanding of the viral and host processes determining outcome of infection with pathogenic flaviviruses (i.e. West Nile virus) to the level allowing most comprehensive design of effective vaccines and anti-viral drugs. One of the aims is also to develop novel viral delivery vectors for cancer therapy based on self-replicating RNA of an attenuated Australian strain of West Nile virus, Kunjin.
A Potent Anti-HIV-1 Gene Therapy Agent In A Humanised Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$1,147,139.00
Summary
We have shown that a synthetic protein called Nullbasic can protect human cells from becoming infected by the AIDS virus, HIV-1. In this project a gene therapy approach will be used to test if a human immune system modified to contain Nullbasic is protected from HIV-1 in an animal model.
Investigating The Altered Landscape Of Enteric Viruses Causing Severe Gastroenteritis In Australian Children Following Rotavirus Vaccine Introduction
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
The rotavirus vaccines were introduced in Australia in 2007, decreasing rotavirus disease. Rotavirus strains naturally evolve during replication, however, high vaccine coverage in the population creates a new environment with different evolutionary pressures where strains not protected by the vaccines may emerge and become dominant. The diminished circulation of rotavirus may create an environment where other viruses capable of causing childhood gastroenteritis may increase.
EEF1A1 Is Critical For HIV-1 Reverse Transcription And Replication
Funder
National Health and Medical Research Council
Funding Amount
$521,429.00
Summary
The project will investigate interaction between the AIDS virus, HIV-1, and the human cell it grows in specifically focusing on a human protein called eEF1A. Our research shows eEF1A is required for HIV-1 growth by regulating a step in the virus life cycle called reverse transcription. The goal of this project is investigate how interaction with eEF1A helps HIV-1 reverse transcription and to find drugs that block HIV-1 interaction with eEF1A.
Chikungunya Virus Disease; The Role Of Proteases And Their Receptors
Funder
National Health and Medical Research Council
Funding Amount
$682,716.00
Summary
Chikungunya virus (CHIKV) is a mosquito borne virus related to the Australian Ross River virus. The arthritic disease caused by these viruses is often poorly managed by current treatments. We have recently identified several proteins call proteases that circulate in the blood of infected people and promote arthritis. If successful the grant will provide new treatment options for these (and perhaps other) diseases using recently developed drugs that inhibit the activity of these proteases.
Novel Early Detection Strategy For Liver Cancer Using Hepatitis B Splice Variants To Expediate Diagnosis And Improve Treatment Outcome
Funder
National Health and Medical Research Council
Funding Amount
$943,566.00
Summary
Hepatitis B virus (HBV) causes liver cancer, which is one of the only cancers that is increasing in prevalence. We have shown that smaller versions of HBV, termed splice variants, are even more strongly associated with liver cancer- people with higher levels of the splice variants were over 3 times more likely to have liver cancer. We will find out why, by thoroughly studying how the splice variants alter the virus and the host cell to promote liver cancer.
The Human Eukaryotic Translation Elongation Factor 1A Is A Paramyxovirus Virus Dependency Factor
Funder
National Health and Medical Research Council
Funding Amount
$585,497.00
Summary
Several paramyxoviruses cause respiratory disease in infants, young children and the elderly worldwide. Another paramyxovirus that can be contracted by people from infected horses, Hendra virus, is often fatal. There are currently no vaccines against these viruses, and treatment is generally limited to relief of symptoms. In this project we will uncover how these viruses use human proteins for their growth inside cells, with an aim to develop novel therapeutic strategies.
Defining Key Mechanisms That Underpin Neuropathogenesis Of Varicella Zoster Virus During Herpes Zoster
Funder
National Health and Medical Research Council
Funding Amount
$616,518.00
Summary
Varicella zoster virus (VZV) is a herpesvirus which causes chicken pox and shingles. Shingles affects many elderly people and a major complication is prolonged severe neuropathic pain, often needing follow-up medical care for months to years. Despite its impact on the community, little is known about how this virus functions and causes disease. We aim to improve our understanding of how VZV interacts with nerve cells to provide essential new information for the development of effective treatment ....Varicella zoster virus (VZV) is a herpesvirus which causes chicken pox and shingles. Shingles affects many elderly people and a major complication is prolonged severe neuropathic pain, often needing follow-up medical care for months to years. Despite its impact on the community, little is known about how this virus functions and causes disease. We aim to improve our understanding of how VZV interacts with nerve cells to provide essential new information for the development of effective treatments for shingles and associated neuropathic pain.Read moreRead less
Chimeric Insect-specific Flaviviruses: A New Generation Of Diagnostics And Vaccines Against Mosquito-borne Viral Disease
Funder
National Health and Medical Research Council
Funding Amount
$549,937.00
Summary
Dengue, Zika and West Nile are mosquito-borne viruses that cause disease outbreaks world-wide. We will develop safe, cheap and authentic diagnostics and vaccines against these diseases based on novel viruses that only infect mosquitoes. This is a timely paradigm shift for vaccine and diagnostic development. This innovative strategy will have high impact in the field of vector-borne viral diseases and provide a blueprint to develop safe diagnostics and vaccines for other mosquito-borne diseases.
Host Genes Controlling Flavivirus Infection: New Insights And Application For Developing Highly Effective Kunjin Replicon-based Ebola Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$736,995.00
Summary
The applications is aimed at identifying new host genes controlling infection with West Nile virus and other medically important flaviviruses such as dengue and Japanese encephalitis. For this, we will use novel in vivo RNAi screening approach with virus libraries encoding artificial microRNAs (amirs) targeting whole mouse genome. We will then apply amiR technology to produce highly effective Kujniin replicon-based Ebola vaccine candidate that has shown promising results in trails in primates.